Predictive Value of CCL2 in the Prognosis and Immunotherapy Response of Glioblastoma Multiforme

Overview

Journal BMC Genomics

Publisher Biomed Central

Specialty Genetics

Date 2023 Dec 6

PMID 38057698

Authors

Longfei Deng

Jie Ren

Benqin Li

Yinggang Wang

Nianfen Jiang

Yi Wang

Hongjuan Cui

Affiliations

Soon will be listed here.

Abstract

Background: Glioblastoma multiforme (GBM) is the most common and lethal primary brain tumor with a poor prognosis. The C-C motif chemokine ligand 2 (CCL2) has shown abnormal expression associated with progression of multiple malignancies, however, its role in predicting the prognosis and immunotherapy response of GBM remains poorly understood.

Results: CCL2 was highly expressed in GBM as analyzed by integrating CGGA, GEPIA and UALCAN online platforms, and further verified by histologic examinations, qRT-PCR analysis, and independent GEO datasets. CCL2 could serve as an independent prognostic factor for both the poor overall survival and progression-free survival of GBM patients based on TCGA data, univariate and multivariate cox analyses. Functional enrichment analysis revealed that CCL2 mainly participated in the regulation of chemokine signaling pathway and inflammatory response. Further, CCL2 expression was positively correlated with CD4 T cells, macrophages, neutrophils and myeloid dendritic cells infiltrating GBM as calculated by the TIMER2.0 algorithm. Importantly, the tumor immune dysfunction and exclusion (TIDE) algorithm showed that in CCL2-high GBM group, the expression of CD274, CTLA4, HAVCR2 and other immune checkpoints were significantly increased, and the immune checkpoint blockade (ICB) therapy was accordingly more responsive.

Conclusions: CCL2 can be used as a predictor of prognosis as well as immunotherapy response in GBM, offering potential clinical implications.

Citing Articles

CCL2 mediated IKZF1 expression promotes M2 polarization of glioma-associated macrophages through CD84-SHP2 pathway.

Song Y, Zhang Y, Wang Z, Lin Y, Cao X, Han X Oncogene. 2024; 43(36):2737-2749.

PMID: 39112517 DOI: 10.1038/s41388-024-03118-w.

References

Hu X, Zhang K, Pan G, Wang Y, Shen Y, Peng C . extracts induce apoptosis and inhibit tumor invasion blockage of the PI3K/AKT signaling in melanoma cells. Front Pharmacol. 2022; 13:1007279. PMC: 9627489. DOI: 10.3389/fphar.2022.1007279. View

Dogan R, Elhofy A, Karpus W . Production of CCL2 by central nervous system cells regulates development of murine experimental autoimmune encephalomyelitis through the recruitment of TNF- and iNOS-expressing macrophages and myeloid dendritic cells. J Immunol. 2008; 180(11):7376-84. DOI: 10.4049/jimmunol.180.11.7376. View

Hao Q, Vadgama J, Wang P . CCL2/CCR2 signaling in cancer pathogenesis. Cell Commun Signal. 2020; 18(1):82. PMC: 7257158. DOI: 10.1186/s12964-020-00589-8. View

Robert C . A decade of immune-checkpoint inhibitors in cancer therapy. Nat Commun. 2020; 11(1):3801. PMC: 7393098. DOI: 10.1038/s41467-020-17670-y. View

Chen C, He W, Huang J, Wang B, Li H, Cai Q . LNMAT1 promotes lymphatic metastasis of bladder cancer via CCL2 dependent macrophage recruitment. Nat Commun. 2018; 9(1):3826. PMC: 6148066. DOI: 10.1038/s41467-018-06152-x. View

Vachher M, Arora K, Burman A, Kumar B . NAMPT, GRN, and SERPINE1 signature as predictor of disease progression and survival in gliomas. J Cell Biochem. 2019; 121(4):3010-3023. DOI: 10.1002/jcb.29560. View

Reichel C, Rehberg M, Lerchenberger M, Berberich N, Bihari P, Khandoga A . Ccl2 and Ccl3 mediate neutrophil recruitment via induction of protein synthesis and generation of lipid mediators. Arterioscler Thromb Vasc Biol. 2009; 29(11):1787-93. DOI: 10.1161/ATVBAHA.109.193268. View

Zhang J, Yan Y, Cui X, Zhang J, Yang Y, Li H . CCL2 expression correlates with Snail expression and affects the prognosis of patients with gastric cancer. Pathol Res Pract. 2017; 213(3):217-221. DOI: 10.1016/j.prp.2016.12.013. View

Yang K, Wu Z, Zhang H, Zhang N, Wu W, Wang Z . Glioma targeted therapy: insight into future of molecular approaches. Mol Cancer. 2022; 21(1):39. PMC: 8822752. DOI: 10.1186/s12943-022-01513-z. View

10.

Zhang G, Tan R, Wan S, Yang R, Hu X, Zhao E . HECTD3 regulates the tumourigenesis of glioblastoma by polyubiquitinating PARP1 and activating EGFR signalling pathway. Br J Cancer. 2022; 127(11):1925-1938. PMC: 9681879. DOI: 10.1038/s41416-022-01970-9. View

11.

Rollins B, Walz A, Baggiolini M . Recombinant human MCP-1/JE induces chemotaxis, calcium flux, and the respiratory burst in human monocytes. Blood. 1991; 78(4):1112-6. View

12.

He X, Xu C . Immune checkpoint signaling and cancer immunotherapy. Cell Res. 2020; 30(8):660-669. PMC: 7395714. DOI: 10.1038/s41422-020-0343-4. View

13.

OConnor T, Heikenwalder M . CCL2 in the Tumor Microenvironment. Adv Exp Med Biol. 2021; 1302:1-14. DOI: 10.1007/978-3-030-62658-7_1. View

14.

Sturm G, Finotello F, List M . Immunedeconv: An R Package for Unified Access to Computational Methods for Estimating Immune Cell Fractions from Bulk RNA-Sequencing Data. Methods Mol Biol. 2020; 2120:223-232. DOI: 10.1007/978-1-0716-0327-7_16. View

15.

Sharma P, Hu-Lieskovan S, Wargo J, Ribas A . Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy. Cell. 2017; 168(4):707-723. PMC: 5391692. DOI: 10.1016/j.cell.2017.01.017. View

16.

Ghandi M, Huang F, Jane-Valbuena J, Kryukov G, Lo C, McDonald 3rd E . Next-generation characterization of the Cancer Cell Line Encyclopedia. Nature. 2019; 569(7757):503-508. PMC: 6697103. DOI: 10.1038/s41586-019-1186-3. View

17.

Huang Y, Cai K, Xu P, Wang L, Huang C, Fang Y . CREBBP/EP300 mutations promoted tumor progression in diffuse large B-cell lymphoma through altering tumor-associated macrophage polarization via FBXW7-NOTCH-CCL2/CSF1 axis. Signal Transduct Target Ther. 2021; 6(1):10. PMC: 7801454. DOI: 10.1038/s41392-020-00437-8. View

18.

Deng L, Lei Y, Liu R, Li J, Yuan K, Li Y . Pyrvinium targets autophagy addiction to promote cancer cell death. Cell Death Dis. 2013; 4:e614. PMC: 3674351. DOI: 10.1038/cddis.2013.142. View

19.

Xu M, Wang Y, Xia R, Wei Y, Wei X . Role of the CCL2-CCR2 signalling axis in cancer: Mechanisms and therapeutic targeting. Cell Prolif. 2021; 54(10):e13115. PMC: 8488570. DOI: 10.1111/cpr.13115. View

20.

Li C, Xu X, Wei S, Jiang P, Xue L, Wang J . Tumor-associated macrophages: potential therapeutic strategies and future prospects in cancer. J Immunother Cancer. 2021; 9(1). PMC: 8728363. DOI: 10.1136/jitc-2020-001341. View